The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses

Journal of Virology

Volumn 90, Issue 6, 2016, Pages 3086-3092

  Pécheur, Eve Isabelle ^a   Borisevich, Viktoriya ^b   Halfmann, Peter ^c   Morrey, John D ^d   Smee, Donald F ^d   Prichard, Mark ^e   Mire, Chad E ^b   Kawaoka, Yoshihiro ^c,f   Geisbert, Thomas W ^b   Polyak, Stephen J ^g  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UTAH STATE UNIVERSITY   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARBIDOL; CIDOFOVIR; VIRUS GLYCOPROTEIN; ANTIVIRUS AGENT; INDOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG STRUCTURE; EBOLAVIRUS; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 8; MAMMAL CELL; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; TACARIBE VIRUS; VESICULOVIRUS; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; INDOLES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; VIRUS INTERNALIZATION; VIRUS REPLICATION; VIRUSES;

EID: 84961160885     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02077-15     Document Type: Article

References (50)

1. Sulkowski MS, Jacobson IM, Nelson DR. 2014. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 370:1560-1561. http://dx.doi.org/10.1056/NEJMc1401726.
2. Anonymous. 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56:247-270.
3. Shaffer JG, Grant DS, Schieffelin JS, Boisen ML, Goba A, Hartnett JN, Levy DC, Yenni RE, Moses LM, Fullah M, Momoh M, Fonnie M, Fonnie R, Kanneh L, Koroma VJ, Kargbo K, Ottomassathien D, Muncy IJ, Jones AB, Illick MM, Kulakosky PC, Haislip AM, Bishop CM, Elliot DH, Brown BL, Zhu H, Hastie KM, Andersen KG, Gire SK, Tabrizi S, Tariyal R, Stremlau M, Matschiner A, Sampey DB, Spence JS, Cross RW, Geisbert JB, Folarin OA, Happi CT, Pitts KR, Geske FJ, Geisbert TW, Saphire EO, Robinson JE, Wilson RB, Sabeti PC, Henderson LA, Khan SH, Bausch DG, Branco LM, et al. 2014. Lassa fever in postconflict Sierra Leone. PLoS Negl Trop Dis 8:e2748. http://dx.doi.org/10.1371/journal.pntd.0002748.
4. Sayler KA, Barbet AF, Chamberlain C, Clapp WL, Alleman R, Loeb JC, Lednicky JA. 2014. Isolation of Tacaribe virus, a Caribbean arenavirus, from host-seeking Amblyomma americanum ticks in Florida. PLoS One 9:e115769. http://dx.doi.org/10.1371/journal.pone.0115769.
5. Moore PS, Chang Y. 1995. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332:1181-1185. http://dx.doi.org/10.1056/NEJM199505043321801.
6. Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. 2014. The new polio eradication end game: rationale and supporting evidence. J Infect Dis 210(Suppl 1):S434-S438. http://dx.doi.org/10.1093/infdis/jiu222.
7. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-2128. http://dx.doi.org/10.1016/S0140-6736(12)61728-0.
8. Gagarinova VM, Ignat'eva GS, Sinitskaia LV, Ivanova AM, Rodina MA, Tur'eva AV. 1993. The new chemical preparation arbidol: its prophylactic efficacy during influenza epidemics. Zh Mikrobiol Epidemiol Immunobiol 1993:40-43.
9. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. 2008. Arbidol: a broadspectrum antiviral compound that blocks viral fusion. Curr Med Chem 15:997-1005. http://dx.doi.org/10.2174/092986708784049658.
10. Brooks MJ, Burtseva EI, Ellery PJ, Marsh GA, Lew AM, Slepushkin AN, Crowe SM, Tannock GA. 2012. Antiviral activity of arbidol, a broadspectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 84:170-181. http://dx.doi.org/10.1002/jmv.22234.
11. Zhao C, Zhao Y, Chai H, Gong P. 2006. Synthesis and in vitro antihepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates. Bioorg Med Chem 14:2552-2558. http://dx.doi.org/10.1016/j.bmc.2005.11.033.
12. Blaising J, Polyak SJ, Pecheur EI. 2014. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84-94. http://dx.doi.org/10.1016/j.antiviral.2014.04.006.
13. Prichard MN, Williams JD, Komazin-Meredith G, Khan AR, Price NB, Jefferson GM, Harden EA, Hartline CB, Peet NP, Bowlin TL. 2013. Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother 57:3518-3527. http://dx.doi.org/10.1128/AAC.00429-13.
14. Sells MA, Chen ML, Acs G. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84:1005-1009. http://dx.doi.org/10.1073/pnas.84.4.1005.
15. Iyer RP, Jin Y, Roland A, Morrey JD, Mounir S, Korba B. 2004. Phosphorothioate di-and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrob Agents Chemother 48:2199-2205. http://dx.doi.org/10.1128/AAC.48.6.2199-2205.2004.
16. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. 2004. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother 48:1766-1772. http://dx.doi.org/10.1128/AAC.48.5.1766-1772.2004.
17. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168-3176. http://dx.doi.org/10.1128/AAC.00356-07.
18. Blaising J, Levy PL, Polyak SJ, Stanifer M, Boulant S, Pecheur EI. 2013. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res 100:215-219. http://dx.doi.org/10.1016/j.antiviral.2013.08.008.
19. Boriskin YS, Pecheur EI, Polyak SJ. 2006. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol J 3:56. http://dx.doi.org/10.1186/1743-422X-3-56.
20. Pecheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ. 2007. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 46: 6050-6059. http://dx.doi.org/10.1021/bi700181j.
21. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Bockmann A, Meier BH, Penin F, Pecheur EI. 2011. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6:e15874. http://dx.doi.org/10.1371/journal.pone.0015874.
22. Jae LT, Brummelkamp TR. 2015. Emerging intracellular receptors for hemorrhagic fever viruses. Trends Microbiol 23:392-400. http://dx.doi.org/10.1016/j.tim.2015.04.006.
23. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG. 2015. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 7:290ra289.
24. Haid S, Pietschmann T, Pecheur EI. 2009. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem 284:17657-17667. http://dx.doi.org/10.1074/jbc.M109.014647.
25. Cooper A, Shaul Y. 2006. Clathrin-mediated endocytosis and lysosomal cleavage of hepatitis B virus capsid-like core particles. J Biol Chem 281: 16563-16569. http://dx.doi.org/10.1074/jbc.M601418200.
26. Helle F, Dubuisson J. 2008. Hepatitis C virus entry into host cells. Cell Mol Life Sci 65:100-112. http://dx.doi.org/10.1007/s00018-007-7291-8.
27. Willingmann P, Barnert H, Zeichhardt H, Habermehl KO. 1989. Recovery of structurally intact and infectious poliovirus type 1 from HeLa cells during receptor-mediated endocytosis. Virology 168:417-420. http://dx.doi.org/10.1016/0042-6822(89)90286-9.
28. Akula SM, Naranatt PP, Walia NS, Wang FZ, Fegley B, Chandran B. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J Virol 77: 7978-7990. http://dx.doi.org/10.1128/JVI.77.14.7978-7990.2003.
29. Lakadamyali M, Rust MJ, Zhuang X. 2006. Ligands for clathrinmediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 124:997-1009. http://dx.doi.org/10.1016/j.cell.2005.12.038.
30. Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M, Hattori T, Sugamura K. 2007. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 81:8722-8729. http://dx.doi.org/10.1128/JVI.00253-07.
31. Vela EM, Zhang L, Colpitts TM, Davey RA, Aronson JF. 2007. Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology 369:1-11. http://dx.doi.org/10.1016/j.virol.2007.07.014.
32. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. 2010. Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 6:e1001110. http://dx.doi.org/10.1371/journal.ppat.1001110.
33. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y. 2010. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 6:e1001121. http://dx.doi.org/10.1371/journal.ppat.1001121.
34. Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T, Feldmann H, Schnittler HJ. 2011. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis 204(Suppl 3):S957-S967. http://dx.doi.org/10.1093/infdis/jir326.
35. Raghu H, Sharma-Walia N, Veettil MV, Sadagopan S, Chandran B. 2009. Kaposi's sarcoma-associated herpesvirus utilizes an actin polymerization-dependent macropinocytic pathway to enter human dermal microvascular endothelial and human umbilical vein endothelial cells. J Virol 83:4895-4911. http://dx.doi.org/10.1128/JVI.02498-08.
36. Greene W, Gao SJ. 2009. Actin dynamics regulate multiple endosomal steps during Kaposi's sarcoma-associated herpesvirus entry and trafficking in endothelial cells. PLoS Pathog 5:e1000512. http://dx.doi.org/10.1371/journal.ppat.1000512.
37. Akhtar J, Shukla D. 2009. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J 276:7228-7236. http://dx.doi.org/10.1111/j.1742-4658.2009.07402.x.
38. Vanarsdall AL, Wisner TW, Lei H, Kazlauskas A, Johnson DC. 2012. PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog 8:e1002905. http://dx.doi.org/10.1371/journal.ppat.1002905.
39. Nemerow GR, Cooper NR. 1984. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology 132:186-198. http://dx.doi.org/10.1016/0042-6822(84)90102-8.
40. Teissier E, Penin F, Pecheur EI. 2011. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 16:221-250. http://dx.doi.org/10.3390/molecules16010221.
41. Nasser ZH, Swaminathan K, Muller P, Downard KM. 2013. Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry. Antiviral Res 100: 399-406. http://dx.doi.org/10.1016/j.antiviral.2013.08.021.
42. Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, de Lamballerie X. 2011. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 90: 99-107. http://dx.doi.org/10.1016/j.antiviral.2011.03.182.
43. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463. http://dx.doi.org/10.1038/nrmicro1645.
44. Perfetto B, Filosa R, De Gregorio V, Peduto A, La Gatta A, de Caprariis P, Tufano MA, Donnarumma G. 2014. In vitro antiviral and immunomodulatory activity of arbidol and structurally related derivatives in herpes simplex virus type 1-infected human keratinocytes (HaCat). J Med Microbiol 63:1474-1483. http://dx.doi.org/10.1099/jmm.0.076612-0.
45. Chai H, Zhao Y, Zhao C, Gong P. 2006. Synthesis and in vitro antihepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates. Bioorg Med Chem 14:911-917. http://dx.doi.org/10.1016/j.bmc.2005.08.041.
46. Guidotti LG, Matzke B, Schaller H, Chisari FV. 1995. High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158-6169.
47. Sainz B, Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18:281-285. http://dx.doi.org/10.1038/nm.2581.
48. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589-595. http://dx.doi.org/10.1038/nm.2341.
49. Brooks MJ, Sasadeusz JJ, Tannock GA. 2004. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr Opin Pulm Med 10:197-203. http://dx.doi.org/10.1097/00063198-200405000-00009.
50. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2:342-346. http://dx.doi.org/10.1038/nm0396-342.